The CROSSING clinical research study is evaluating the safety and efficacy of tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients who are 12 years of age or older.

EoE is a condition that causes chronic inflammation in the esophagus and is characterized by a build-up of white blood cells, called eosinophils. The inflammation in the esophagus can make it difficult or painful to swallow food.

Patients may be able to join the study if they:

• Are between 12–80 years of age
• Have been diagnosed with EoE
• Have problems with swallowing on a regular basis
• Have been treated for EoE before OR are currently receiving treatment for EoE

If patient is eligible to take part:

• Will receive expert medical care, related to the study, at no cost to patient
• May receive compensation, relating to time and travel costs
• Will help to make a difference for people diagnosed with EoE in the future

During this study patient may receive an experimental treatment which is being evaluated for EoE. As the treatment is experimental, its safety and efficacy in EoE has not yet been established.